Can metformin extend lifespan in non-diabetic individuals?

Does metformin actually extend lifespan in non-diabetics?

The strongest human evidence comes from studies of people with type 2 diabetes, not healthy individuals. A large 2023 study of over 129,000 people with type 2 diabetes in Wales found that metformin users initially had better survival than matched non-diabetic controls, but this benefit disappeared after five years of treatment, and over a full 20-year period, metformin users actually had shorter survival than non-diabetics [4]. This suggests that while metformin may offer short-term benefits, it does not overcome the long-term negative effects of diabetes on lifespan. For non-diabetics, direct evidence is lacking—no large, long-term trials have been completed.

Animal studies provide a more mixed picture. A 2022 meta-analysis of experiments in mice and nematode worms found that metformin did not significantly extend lifespan overall [11]. However, in worms, it did extend lifespan when started early in life and when using live bacteria as a food source, hinting that timing and context matter [11]. In rats, long-term metformin improved memory and reduced oxidative stress in the brain, but lifespan was not measured [2]. These findings suggest metformin may influence aging processes, but translating this to human lifespan extension is uncertain.

A 2025 review of the evidence concluded that early, influential studies suggesting metformin could extend lifespan in humans had methodological flaws, and more recent trials in non-diabetics have not confirmed these benefits [9]. The authors describe an 'emerging uncertainty' about metformin's anti-aging potential [9].

What other health benefits might metformin offer non-diabetics?

Even if metformin doesn't clearly extend lifespan, it may improve 'healthspan'—the period of life free from disease. A 2025 scoping review of 56 studies found that metformin improved markers of endothelial dysfunction (a key factor in heart disease) in non-diabetic conditions, particularly in polycystic ovary syndrome [1]. However, the effect was modest: only 7 out of 19 biomarkers showed improvement, and most positive results came from studies without a placebo control, which weakens the evidence [1].

Metformin also shows promise for kidney health. In rats with non-diabetic chronic kidney disease, metformin halted further kidney decline and reduced inflammation and scarring [6][7]. In a mouse model of Alport syndrome (a genetic kidney disease), metformin extended lifespan and reduced kidney damage [10]. These effects were independent of blood sugar control, suggesting metformin may protect kidneys through other mechanisms, like activating the AMPK pathway [12].

For cancer, a 2026 study of over 94,000 non-diabetic men found that metformin use in obese men was associated with a reduced risk of advanced prostate cancer, but only if detected early [3]. This is an observational finding, not proof of cause and effect.

However, metformin is not without risks. A 2022 study in non-diabetic rats found that metformin prolonged cardiac repolarization (the QT interval on an ECG), which can increase the risk of dangerous heart arrhythmias [8]. This effect was seen at therapeutic doses, raising a safety concern for healthy individuals taking metformin for longevity.

Who might benefit from metformin, and what are the caveats?

Based on the evidence, the people most likely to benefit from metformin are those with specific health conditions, not healthy individuals seeking to extend lifespan. For example, people with polycystic ovary syndrome or early-stage chronic kidney disease might see improvements in vascular or kidney function [1][6]. Obese men might have a lower risk of advanced prostate cancer [3]. But these are specific, disease-related benefits, not general longevity.

Timing matters. In animal studies, metformin was more effective when started early in life [11]. In humans, the short-term survival benefit seen in diabetics suggests that if metformin has any lifespan effect, it may be most pronounced in the first few years of use [4]. Long-term use beyond five years may not provide additional benefit and could even be harmful, as seen in the reversal of survival advantage [4].

Crucially, metformin is a prescription drug with known side effects (gastrointestinal issues, lactic acidosis risk) and potential cardiac risks [8]. The evidence does not support its use as a 'longevity pill' for healthy, non-diabetic individuals. The authors of a 2025 review explicitly state that 'well-designed randomized controlled trials are required to confirm its efficacy and safety in the context of healthy aging' [5]. Until those trials are done, the answer to the question 'Can metformin extend lifespan in non-diabetic individuals?' remains: we don't know for sure, and the current evidence suggests it's unlikely to be a simple, safe solution.

About These Sources

This answer is built on 12 peer-reviewed studies — published from 2021 to 2026, 4 from 2024 or later, 8 in Q1 journals, collectively cited 725 times — selected as the most relevant from 13 studies that passed quality screening, drawn from 59 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions